Literature DB >> 31257517

Long non‑coding RNA DLEU1 promotes cell proliferation of glioblastoma multiforme.

Jiancun Wang1, Xingyun Quan1, Dingting Peng1, Guancheng Hu1.   

Abstract

Glioblastoma multiforme (GBM) is the most common malignant tumor with high morbidity and mortality. This study investigated the role of long non‑coding RNAs (lncRNAs) in glioblastomagenesis progression. Using the GSE2223 and GSE59612 datasets, and RNA sequencing data of GBM from The Cancer Genome Atlas, differentially expressed (DE) genes including DE messenger RNAs (DEmRNAs) and DElncRNAs between GBM and normal controls were identified. Based on the competing endogenous RNA hypothesis, DElncRNA‑micro RNA (miRNA)‑DEmRNA interactions were obtained by target gene prediction. Gene Ontology (GO) and Kyoto Encyclopedia of Gene and Genomes pathway analysis of DEmRNAs in the DElncRNA‑miRNA‑DEmRNA network was performed. Expression and function analyses of DElncRNAs were performed by reverse transcription‑polymerase chain reaction (RT‑PCR) and an established viability assay, respectively. In total, 712 DE genes were identified. Significant upregulation of lncRNA deleted in lymphocytic leukemia 1 (DLEU1) was revealed in GBM and a number of other types of cancer. DLEU1 interacted with 315 miRNAs and 105 DEmRNAs. The DEmRNAs were mainly enriched in tumorigenesis‑associated GO terms (angiogenesis, positive regulation of cell proliferation, positive regulation of fibroblast apoptotic processes and regulation of neutrophil migration) and pathways (Hippo signaling pathway, cancer pathways, and Wnt signaling pathway). Correlation analysis revealed that mRNA TNF receptor associated factor 4 (TRAF4) was associated with DLEU1 expression. RT‑PCR demonstrated that the expression levels of DLEU1 and TRAF4 were increased in GBM tissues. Small interfering RNA demonstrated that silencing DLEU1 downregulated TRAF4. The viability of GBM cells was significantly decreased following RNA interference with DLEU1 and TRAF4 production. The results demonstrate that DLEU1 and TRAF4 is highly expressed in GBM tissues and promotes proliferation of GBM cells. It may act as a competing endogenous RNA and influence tumorigenesis of GBM.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31257517     DOI: 10.3892/mmr.2019.10428

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  6 in total

1.  TRAF4 knockdown triggers synergistic lethality with simultaneous PARP1 inhibition in endometrial cancer.

Authors:  Liulin Tang; Min Wang; Li Jiang; Chengying Zeng
Journal:  Hum Cell       Date:  2020-05-09       Impact factor: 4.174

Review 2.  Emerging Role of Long Non-Coding RNAs in the Pathobiology of Glioblastoma.

Authors:  Omidvar Rezaei; Kasra Honarmand Tamizkar; Guive Sharifi; Mohammad Taheri; Soudeh Ghafouri-Fard
Journal:  Front Oncol       Date:  2021-02-03       Impact factor: 6.244

3.  Knockdown lncRNA DLEU1 Inhibits Gliomas Progression and Promotes Temozolomide Chemosensitivity by Regulating Autophagy.

Authors:  Qiao-Li Lv; Li-Chong Wang; Dang-Chi Li; Qian-Xia Lin; Xiao-Li Shen; Hai-Yun Liu; Min Li; Yu-Long Ji; Chong-Zhen Qin; Shu-Hui Chen
Journal:  Front Pharmacol       Date:  2020-12-09       Impact factor: 5.810

Review 4.  Advances in Understanding the LncRNA-Mediated Regulation of the Hippo Pathway in Cancer.

Authors:  Mengwei Wang; Tianwei Xu; Wenyan Feng; Junxia Liu; Zhaoxia Wang
Journal:  Onco Targets Ther       Date:  2021-04-07       Impact factor: 4.147

Review 5.  The Research Progress in Physiological and Pathological Functions of TRAF4.

Authors:  Xueqin Ruan; Rong Zhang; Ruijuan Li; Hongkai Zhu; Zhihua Wang; Canfei Wang; Zhao Cheng; Hongling Peng
Journal:  Front Oncol       Date:  2022-02-15       Impact factor: 6.244

6.  Exploring the potential biomarkers for prognosis of glioblastoma via weighted gene co-expression network analysis.

Authors:  Mengyuan Zhang; Zhike Zhou; Zhouyang Liu; Fangxi Liu; Chuansheng Zhao
Journal:  PeerJ       Date:  2022-01-18       Impact factor: 2.984

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.